CD274 and neoplasm: The combination of FABP5‐targeted nanotherapy, RFA, and anti‐PD‐L1 synergistically suppresses tumor progression and metastasis, highlighting FABP5 as a promising diagnostic marker and therapeutic target in hepatocellular carcinoma.